ArticleJournal of managed care & specialty pharmacy2026
Association of diabetes medication adherence quality measure performance with A1c control among Medicare Advantage beneficiaries.
Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Centers for Medicare & Medicaid Services provide financial incentives for insurance plans demonstrating high-quality care to improve patient outcomes. Medicare Advantage (MA) plan performance is assessed by nearly 40 quality measures, with diabetes care heavily represented by 5 of those measures. Medication Adherence for Diabetes (MAD) and Hemoglobin A1c Control for Patients with Diabetes (HBD) are emphasized as triple-weighted measures that strongly impact the overall quality rating. The national average ratings for MA Prescription Drug (MA-PD) plans from 2022 to 2026 show a flat average pass rate 5 years in a row for the MAD measure but a steadily increasing pass rate each year for the HBD measure. Observation of this trend, along with rising 4- and 5-star cut points, raise questions about whether the MAD measure methodology currently contributes to the achievement of clinical outcomes in patients with diabetes and whether it guides health care resources to the population in need.
objectiveTo identify the relationship between MAD performance and hemoglobin A1c (A1c) control. Secondary objectives were to evaluate the relationship between MAD and additional diabetes care quality measures and to evaluate factors associated with MAD measure performance.
methodsThis cross-sectional study included Aetna MA beneficiaries attributed to Prisma Health primary care providers participating in the inVio Health Network who indexed into the MAD measure during the 2023 measurement year. Data were collected from January 1, 2023, to December 31, 2023. The primary outcome was glycemic control, defined as achievement of A1c of less than 7%. Secondary outcomes included HBD, Eye Exam for Patients with Diabetes (EED), Statin Use in Persons with Diabetes (SUPD), and Kidney Health Evaluation for Patients with Diabetes (KED). Associations between MAD performance with A1c and diabetes quality measures were evaluated using descriptive statistics, χ
resultsThe final study population included 1,386 beneficiaries (mean age = 72.3 years; 50.5% male). Among beneficiaries with available A1c values (n = 1,278), mean A1c did not differ significantly between those who passed and those who failed the MAD measure (6.80 ± 0.98% vs 6.66 ± 1.16%;
conclusionsMAD performance was not independently associated with better glycemic control in our study population. The current proportion of days covered-based MAD measure methodology may not capture true medication adherence or its clinical impact and warrants reevaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.